Boulos Mark I, Chi Luqi, Chernyshev Oleg Y
Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Front Neurol. 2022 Oct 28;13:1032463. doi: 10.3389/fneur.2022.1032463. eCollection 2022.
Undiagnosed obstructive sleep apnea (OSA) is prevalent in neurological practice and significantly contributes to morbidity and mortality. OSA is prevalent in US adults and causes poor quality sleep and significant neurocognitive, cardiovascular, and cerebrovascular impairments. Timely treatment of OSA reduces cardio-cerebrovascular risks and improves quality of life. However, most of the US population has limited systematic access to sleep medicine care despite its clinical significance.
We discuss the importance of systematic screening, testing, and best-practice management of OSA and hypoventilation/hypoxemia syndromes (HHS) in patients with stroke, neurocognitive impairment, and neuromuscular conditions. This review aims to introduce and describe a novel integrated Mobile Sleep Medicine (iMSM) care model and provide the rationale for using an iMSM in general neurological practice to assist with systematic screening, testing and best-practice management of OSA, HHS, and potentially other sleep conditions.
The iMSM is an innovative, patient-centered, clinical outcome-based program that uses a Mobile Sleep Medicine Unit-a "sleep lab on wheels"-designed to improve access to OSA management and sleep care at all levels of health care system. The protocol for the iMSM care model includes three levels of operations to provide effective and efficient OSA screening, timely testing/treatment plans, and coordination of further sleep medicine care follow-up. The iMSM care model prioritizes effective, efficient, and patient-centered sleep medicine care; therefore, all parties and segments of care that receive and provide clinical sleep medicine services may benefit from adopting this innovative approach.
未诊断出的阻塞性睡眠呼吸暂停(OSA)在神经科临床中很常见,并且对发病率和死亡率有显著影响。OSA在美国成年人中普遍存在,会导致睡眠质量差以及严重的神经认知、心血管和脑血管损害。及时治疗OSA可降低心脑血管风险并改善生活质量。然而,尽管其具有临床意义,但大多数美国人群获得睡眠医学护理的系统途径有限。
我们讨论了对中风、神经认知障碍和神经肌肉疾病患者进行OSA以及通气不足/低氧血症综合征(HHS)的系统筛查、检测和最佳实践管理的重要性。本综述旨在介绍和描述一种新型的综合移动睡眠医学(iMSM)护理模式,并提供在一般神经科实践中使用iMSM以协助对OSA、HHS以及潜在的其他睡眠状况进行系统筛查、检测和最佳实践管理的基本原理。
iMSM是一个创新的、以患者为中心、基于临床结果的项目,它使用移动睡眠医学单元——一个“车轮上的睡眠实验室”,旨在改善在医疗保健系统各级获得OSA管理和睡眠护理的机会。iMSM护理模式的方案包括三个操作层面,以提供有效且高效的OSA筛查、及时的检测/治疗计划以及进一步睡眠医学护理随访的协调。iMSM护理模式将有效、高效且以患者为中心的睡眠医学护理放在首位;因此,所有接受和提供临床睡眠医学服务的护理方和环节都可能从采用这种创新方法中受益。